Phocas Financial Corp’s Nurix Therapeutics NRIX Stock Holding History

Phocas Financial Corp’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.42M	Buy	+99,589	New	+$1.7M	0.34%	111

Other funds holding NRIX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WFA

WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

VIG

Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Phocas Financial Corp's NRIX Position: Q2 2026 in Review

Phocas Financial Corp opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 99,589 shares worth $2.42M. The stake represents 0.34% of the portfolio and ranks #111 among its holdings.

36 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Phocas Financial Corp held 99,589 shares of Nurix Therapeutics worth $2.42M as of Q2 2026.
Nurix Therapeutics was a new Phocas Financial Corp position in Q2 2026.
Nurix Therapeutics made up 0.34% of Phocas Financial Corp's portfolio in Q2 2026, its #111 holding.
36 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.